Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
Sophia LivaMin ChenAmir MortazaviAlison WalkerJiang WangKristin DittmarCraig HofmeisterChristopher C CossMitch A PhelpsPublished in: European journal of drug metabolism and pharmacokinetics (2021)
FFM was identified as a significant covariate on CL; however, it explained only a very small portion of the IIV; major factors contributing significantly to REC-2282 pharmacokinetic variability remain unidentified.